NICE Approves Enfortumab Vedotin + Pembrolizumab as First-line Treatment for Adults with Metastatic Urothelial Cancer in the UK

Enfortumab vedotin (Padvec™; Astellas Pharma and Pfizer) in combination with pembrolizumab (Keytruda®; Merck & Co/Merck Sharp & Dohme) has been approved a a first-line treatment by the National Institute for Health and Care Excellence (NICE) for prescription for unresectable or metastatic urothelial cancer in the United Kingdom (UK).

Publication Details

Journal
ADC Review / Journal of Antibody-drug Conjugates
Published
2025-09-12
DOI
https://doi.org/10.14229/jadc.2025.09.12.002
Primary Topic
Bladder and Urothelial Cancer Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

NICE Approves Enfortumab Vedotin + Pembrolizumab as First-line Treatment for Adults with Metastatic Urothelial Cancer in the UK

ADC Review / Journal of Antibody-drug Conjugates
Bladder and Urothelial Cancer Treatments
article

NICE Approves Enfortumab Vedotin + Pembrolizumab as First-line Treatment for Adults with Metastatic Urothelial Cancer in the UK

article en

Abstract

Enfortumab vedotin (Padvec™; Astellas Pharma and Pfizer) in combination with pembrolizumab (Keytruda®; Merck & Co/Merck Sharp & Dohme) has been approved a a first-line treatment by the National Institute for Health and Care Excellence (NICE) for prescription for unresectable or metastatic urothelial cancer in the United Kingdom (UK).

ADC Review / Journal of Antibody-drug Conjugates
Openalex Percentile: Top 59%
Bladder and Urothelial Cancer Treatments
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

NICE Approves Enfortumab Vedotin + Pembrolizumab as First-line Treatment for Adults with Metastatic Urothelial Cancer in the UK · ADC Review / Journal of Antibody-drug Conjugates (2025) | TGRS Research Map | TGRS